AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2021. The put-call ratio across all filers is 0.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,611 | -33.3% | 738,906 | +6.8% | 0.01% | -18.8% |
| Q2 2023 | $11,406 | +51.9% | 692,106 | -15.6% | 0.02% | +60.0% |
| Q1 2023 | $7,509 | +52.9% | 819,754 | +19.5% | 0.01% | +42.9% |
| Q4 2022 | $4,910 | -99.9% | 685,806 | -13.1% | 0.01% | +16.7% |
| Q3 2022 | $3,952,000 | +89.6% | 788,906 | -7.6% | 0.01% | +200.0% |
| Q2 2022 | $2,084,000 | -59.5% | 854,006 | +13.2% | 0.00% | -66.7% |
| Q1 2022 | $5,152,000 | -24.6% | 754,306 | -10.8% | 0.01% | -33.3% |
| Q4 2021 | $6,834,000 | -18.3% | 845,806 | -0.9% | 0.01% | -18.2% |
| Q3 2021 | $8,362,000 | +41.8% | 853,306 | -2.6% | 0.01% | +57.1% |
| Q2 2021 | $5,899,000 | -29.8% | 876,506 | -5.7% | 0.01% | -30.0% |
| Q1 2021 | $8,401,000 | +20.2% | 929,306 | -11.2% | 0.01% | +25.0% |
| Q4 2020 | $6,989,000 | +12.1% | 1,046,306 | -15.4% | 0.01% | +33.3% |
| Q3 2020 | $6,233,000 | -42.4% | 1,236,683 | -7.6% | 0.01% | -33.3% |
| Q2 2020 | $10,815,000 | +50.4% | 1,338,491 | +47.8% | 0.01% | +28.6% |
| Q1 2020 | $7,192,000 | +11.5% | 905,806 | +6.1% | 0.01% | +40.0% |
| Q4 2019 | $6,448,000 | +88.5% | 854,006 | +3.9% | 0.01% | +66.7% |
| Q3 2019 | $3,420,000 | +47.4% | 822,006 | +2.4% | 0.00% | +50.0% |
| Q2 2019 | $2,320,000 | +144.7% | 802,606 | +21.9% | 0.00% | +100.0% |
| Q1 2019 | $948,000 | -40.9% | 658,336 | +5.9% | 0.00% | -50.0% |
| Q4 2018 | $1,603,000 | -36.9% | 621,500 | +7.3% | 0.00% | -33.3% |
| Q3 2018 | $2,542,000 | -79.0% | 579,135 | -68.4% | 0.00% | -57.1% |
| Q2 2018 | $12,130,000 | +112.8% | 1,830,870 | +134.2% | 0.01% | +16.7% |
| Q1 2018 | $5,699,000 | -39.3% | 781,800 | -31.7% | 0.01% | -40.0% |
| Q4 2017 | $9,386,000 | +8.5% | 1,144,600 | +39.0% | 0.01% | 0.0% |
| Q3 2017 | $8,649,000 | +12.3% | 823,700 | +18.0% | 0.01% | 0.0% |
| Q2 2017 | $7,702,000 | +6597.4% | 698,273 | +5767.8% | 0.01% | – |
| Q1 2017 | $115,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |